Ann: Best and Final Confirmation and Bridging Loan, page-242

One paragraph caught my attention. See below.

Biotech mergers have picked up and some expect more deals ahead, as big pharmaceutical companies sitting on cash, such as Pfizer Inc. with $33 billion, search for attractive biotech companies. Earlier this month, Pfizer agreed to buy Global Blood Therapeutics Inc., a biotech company that has one of the few approved treatments for sickle-cell disease, for $5.4 billion in cash. Profits from Pfizer’s Covid-19 vaccine have given the company the wherewithal to make more deals, investors say.